Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
-
Catheter Cardiovasc Interv · Oct 2013
Case ReportsVery late erosion of Amplatzer septal occluder device presenting as pericardial pain and effusion 8 years after placement.
We report the case of a very late erosion of an Amplatzer septal occluder (ASO) device more than 8 years after implant, presenting without signs of cardiac tamponade. To date, this case represents the longest period between ASO device implantation and clinical presentation following erosion. The overall rate of device erosion remains low, and the majority reported so far has occurred early, but clinicians should remain alert to the possibility of very late erosion in patients with ASO devices.
-
Catheter Cardiovasc Interv · Oct 2013
Recurrent events after percutaneous closure of patent foramen ovale.
To determine the incidence of symptomatic recurrent embolic events after patent foramen ovale (PFO) closure and potential causes for these events. ⋯ The incidence of symptomatic embolic events after PFO closure is low. Most recurrent events are related to coexistent conditions associated with thromboembolic risk rather than residual shunts.
-
Catheter Cardiovasc Interv · Oct 2013
Staged total percutaneous treatment of aortic valve pathology and mitral regurgitation: institutional experience.
To summarize our single Institution experience with staged total percutaneous management of aorto-mitral pathology. ⋯ Percutaneous treatment of AVS and MVR is feasible and safe. A tailored approach should be considered to treat firstly the AVS and subsequently the MVR when severe MV dysfunction and symptoms persist. Short-term durability of this combined percutaneous approach seems encouraging and justifies the economical burden to treat patients that have no other option.
-
Catheter Cardiovasc Interv · Oct 2013
Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy.
This study was undertaken to evaluate the safety of bivalirudin (BIV) use during percutaneous coronary intervention (PCI), following thrombolytic therapy in patients with ST-segment elevation myocardial infarction (STEMI). ⋯ The use of BIV in patients presenting with STEMI who were pretreated with thrombolytic therapy and who subsequently underwent PCI is safe and is associated with less ischemic and bleeding events when compared with UFH, and should be considered as the first line anticoagulant for these patients during PCI.
-
Catheter Cardiovasc Interv · Oct 2013
Percutaneous recanalization of totally occluded pulmonary veins after pulmonary vein isolation-intermediate-term follow-up.
Review mid-term follow-up of percutaneous intervention for post ablation total pulmonary vein occlusion (PVO). ⋯ Recanalization of total PVO can be accomplished with reasonable mid-term patency, improved symptoms, and lung perfusion. Reocclusion is common, but vessel growth is often observed allowing placement of a reasonably sized stent at a second intervention. Staged intervention is often necessary to maintain patency.